Bart van den Bemt
Overview
Explore the profile of Bart van den Bemt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
247
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hazen A, Pouls B, Nazar H, Fialova D, Alraisi F, van den Bemt B
Int J Clin Pharm
. 2024 Nov;
46(6):1245-1246.
PMID: 39535686
No abstract available.
2.
Van den Bemt P, Blijham M, Ten Broek L, Hugtenburg J, Pouls B, van Boven J, et al.
Eur J Hosp Pharm
. 2024 Jul;
PMID: 39019578
Objectives: Patients on oral anticancer therapy regularly experience medication-related problems (MRPs), potentially leading to non-adherence and medication waste. Most studies reporting these experiences have cross-sectional designs. The aim of our...
3.
van der Togt C, van den Bemt B, Aletaha D, Alten R, Chatzidionysiou K, Galloway J, et al.
RMD Open
. 2023 Mar;
9(1).
PMID: 36863753
Objectives: To develop evidence-based points to consider for cost-effective use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the treatment of inflammatory rheumatic diseases, specifically rheumatoid arthritis, psoriatic...
4.
Gieling J, van den Bemt B, Hoppenreijs E, Schatorje E
Pediatr Rheumatol Online J
. 2022 Dec;
20(1):109.
PMID: 36471348
Background: Biologic disease-modifying antirheumatic drugs (bDMARDs) have changed the treatment of juvenile idiopathic arthritis (JIA) patients notably, as bDMARDs enable substantially more patients to achieve remission. When sustained remission is...
5.
Pouls B, Bekker C, Gundogan F, Hebing R, van Onzenoort H, van de Ven L, et al.
RMD Open
. 2022 Nov;
8(2).
PMID: 36410776
Objective: To examine the effect on adherence to disease modifying anti-rheumatic drugs (DMARDs) in participants with rheumatoid arthritis (RA) of a serious game that targeted implicit attitudes toward medication. Methods:...
6.
van de Meeberg M, Hebing R, Nurmohamed M, Fidder H, Heymans M, Bouma G, et al.
Br J Clin Pharmacol
. 2022 Nov;
89(1):61-79.
PMID: 36326810
Aims: In immune-mediated inflammatory diseases (IMIDs), early symptom control is a key therapeutic goal. Methotrexate (MTX) is the first-line treatment across IMIDs. However, MTX is underutilized and suboptimally dosed, partly...
7.
Dreischulte T, van den Bemt B, Steurbaut S
Int J Clin Pharm
. 2022 Jun;
44(4):837-842.
PMID: 35668277
Many definitions of the term clinical pharmacy exist, but a number of ambiguities remain. In order to clarify the European Society of Clinical Pharmacy (ESCP) position on what defines clinical...
8.
van Riet-Nales D, van den Bemt B, van Bodegom D, Cerreta F, Dooley B, Eggenschwyler D, et al.
Br J Clin Pharmacol
. 2022 Feb;
88(4):1500-1514.
PMID: 35141926
Older people are often affected by impaired organ and bodily functions resulting in multimorbidity and polypharmacy, turning them into the main user group of many medicines. Very often, medicines have...
9.
Hebing R, Aksu I, Twisk J, Bos W, van den Bemt B, Nurmohamed M
RMD Open
. 2022 Feb;
8(1).
PMID: 35121638
Objective: Medication non-adherence in rheumatoid arthritis (RA) is associated with disease flares, increased disability and increased costs. This study assessed the effectiveness of electronic monitoring feedback (EMF) on medication adherence...
10.
Papastergiou J, Quilty L, Li W, Thiruchselvam T, Jain E, Gove P, et al.
Clin Transl Sci
. 2021 Feb;
14(4):1359-1368.
PMID: 33641259
The literature on pharmacogenomics as a tool to support antidepressant precision is burgeoning. Recently, a more active role has been argued for pharmacists in pharmacogenomic testing, with both pharmacists and...